Céline Lobry

Fixed-dose rate gemcitabine alone or alternating with FOLFIRI.3 (irinotecan, leucovorin and fluorouracil) in the first-line treatment of patients with metastatic pancreatic adenocarcinoma: An AGEO randomised phase II study (FIRGEM)

Isabelle Trouilloud, Anne-Claire Dupont-Gossard, David Malka et al. · European Journal of Cancer · 2014 · 37 citations

Medicine, Oncology, Pharmacology +16

Prognostic value of health-related quality of life in patients with metastatic pancreatic adenocarcinoma: a random forest methodology

Momar Diouf, Thomas Filleron, Anne‐Laure Pointet et al. · Quality of Life Research · 2015 · 33 citations

Medicine, Biostatistics, Oncology +14

A Reappraisal of Chemotherapy-Induced Liver Injury in Colorectal Liver Metastases before the Era of Antiangiogenics

Éric Nguyen-Khac, Céline Lobry, Denis Chatelain et al. · International Journal of Hepatology · 2013 · 23 citations · Full text

Medicine, Oncology, Pharmacology +17

Somatostatin receptor scintigraphy screening in advanced hepatocarcinoma: A multicenter French study

Éric Nguyen-Khac, Isabelle Ollivier, Thomas Aparicio et al. · Cancer Biology & Therapy · 2009 · 12 citations

Medicine, Nuclear Medicine, Oncology +17

FOLFIRI.3 (CPT-11 plus folinic acid plus 5-FU) alternating with gemcitabine or gemcitabine (G) alone in patients (pts) with previously untreated metastatic pancreatic adenocarcinoma (MPA): Results of the randomized multicenter AGEO phase II trial FIRGEM.

Isabelle Trouilloud, Anne Claire Dupont-Gossard, Pascal Artru et al. · Journal of Clinical Oncology · 2012 · 10 citations

Medicine, Oncology, Pharmacology +14